Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD
Portfolio Pulse from Benzinga Newsdesk
Mesoblast Limited (NASDAQ:MESO) will file a Biologics License Application (BLA) with the FDA for Ryoncil® (remestemcel-L) to treat pediatric steroid-refractory acute graft versus host disease (SR-aGVHD).
July 01, 2024 | 6:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mesoblast Limited is set to file a BLA with the FDA for Ryoncil® to treat pediatric SR-aGVHD, which could significantly impact the company's market position and stock price.
Filing a BLA with the FDA is a critical step towards gaining approval for a new treatment. If approved, Ryoncil® could address a significant unmet medical need, potentially boosting Mesoblast's market position and stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100